Clinical trials: Acute Ischaemic Stroke
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 34 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Ischemic Stroke
Assess the Penumbra System in the Treatment of Acute Stroke
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke…
- Trial name
- THERAPY (NCT01429350)
- Testing
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Penumbra Inc.
Ischemic Stroke
A Phase Ib/II in Patients With Acute Ischemic Stroke
Stroke is the fifth leading cause of death in the United States and is the leading cause of long term disability. Distinct geographic disparities in stroke mortality, with highest rates in the southeast United States including…
- Trial name
- NCT02963376
- Testing
- 0.05 mL/kg DDFPe, 0.10 mL/kg DDFPe, 0.17 mL/kg DDFPe
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NuvOx LLC
AIS, Acute Ischemic Stroke
A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel occlusion in the cerebral circulation.
- Conditions
- AIS, Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy
- Trial name
- NCT05496361
- Testing
- Tianyi Revascularization Device, Solitaire FR Revascularization Device
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Stroke, Acute, Stroke, Ischemic
Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy
Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high.
- Trial name
- NCT06514976
- Testing
- Cytoflavin
- Where
- 17 sites in Russia
- Volunteers
- 562 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 257 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Stent Thrombosis, Ischemic Stroke
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
The goal of this study is to predict and prevent adverse drug events by investigating the impact of genetic variants, demographics, and environmental factors in subjects status post myocardial infarction and percutaneous coronary…
- Conditions
- Stent Thrombosis, Ischemic Stroke, Myocardial Infarction, Acute Coronary Syndrome
- Trial name
- CARES1 (NCT04580602)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Acute Ischemic Stroke
Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated With Neurothrombectomy Devices in India
PRAAN is a post-market registry designed to collect real-world data associated with the use of Medtronic market release neurothrombectomy devices in acute ischemic stroke (AIS) patients from India.
- Trial name
- PRAAN (NCT05005962)
- Testing
- Neurothrombectomy
- Where
- 14 sites in India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Ischemic Stroke
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients with ischemic stroke in comparison to alteplase.
- Trial name
- NCT03151993
- Testing
- Recombinant staphylokinase, Alteplase
- Where
- 18 sites in Russia
- Volunteers
- 336 people
- Sponsor
- Supergene, LLC
Stroke
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a…
- Trial name
- REGENESIS (NCT00715364)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stem Cell Therapeutics Corp.
Stroke, Ischemic
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the…
- Trial name
- XY03-EA (NCT06755944)
- Testing
- XY03-EA 150 mg (per dose), XY03-EA 300 mg (Regimen A), XY03-EA 300 mg (Regimen B)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Acute Ischemic Stroke
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Post-Market Registry
- Trial name
- RECANOVA (NCT07599904)
- Testing
- Mechanical Thrombectomy
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Stroke
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
The purpose of this study is: To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS-LED (NCT00938314)
- Testing
- human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Stem Cell Therapeutics Corp.
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke AIS
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1.
- Trial name
- NCT07903701
- Testing
- SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II)
- Volunteers
- 1,092 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Stroke, Acute Stroke
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT07751328
- Testing
- Axana Scan and MRI
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wellumio R&D Australia Pty Ltd
Cardiovascular Disease, Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial…
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Trial name
- EVOLVE-MI (NCT05284747)
- Testing
- Evolocumab, Routine Lipid Management
- Where
- 120 sites in United States, Brazil and 1 more
- Volunteers
- 6,019 people
- Sponsor
- Amgen
Ischemic Stroke
Evaluation of the Safety and Performance of Magneto Microcatheter
A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Microcatheter in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.
- Trial name
- NCT04466033
- Testing
- Magneto Microcatheter
- Where
- 3 sites in Hungary, Israel
- Volunteers
- 4 people
- Sponsor
- Magneto Thrombectomy Solutions
Acute Ischemic Stroke
Efficacy and Safety Evaluation of the Thromboaspiration Catheter System iNstroke in Patients With Acute Ischemic Stroke
First prospective, single-arm, single-centre study to evaluate the efficacy and safety of the iNstroke thromboaspiration catheter system (iNstroke) for stroke in patients with acute ischemic stroke.
- Trial name
- ASPiC (NCT05720975)
- Testing
- iNstroke
- Where
- Spain
- Volunteers
- 113 people
- Sponsor
- iVascular S.L.U.